PTAB challenges

Proceedings overview

There is one AIA trial proceeding on file for US Patent 10,603,183, which is currently pending. As there are no final decisions yet, all claims remain untested by the PTAB.

IPR2026-00285 — Medtronic, Inc. v. Moskowitz Family LLC

• Type: Inter Partes Review
• Filed: 2026-03-02
• Status: Pending (The proceeding is ongoing and has not yet reached a final decision regarding institution or merits.)
• Judge panel: Not yet publicly available
• Petition grounds: The petition by Medtronic, Inc. challenges claims 1-20 of U.S. Patent No. 10,603,183. The grounds asserted include anticipation under 35 U.S.C. § 102(a) and obviousness under 35 U.S.C. § 103(a), based on various prior art references including U.S. Patent No. 7,704,279 (Moskowitz '279), U.S. Patent No. 7,846,188 (Moskowitz '188), and U.S. Patent No. 7,942,903 (Moskowitz '903). These references are cited alone or in various combinations.
• Institution decision: Not yet issued. The statutory deadline for the institution decision is 2026-09-02.
• Final Written Decision: Not yet issued.
• Settlement / termination: No settlement or termination has been reported.
• Appeal: No appeal has been filed as no Final Written Decision has been issued.
• Defensive value: This IPR is in its early stages. If instituted, it could lead to cancellation of some or all of the challenged claims, which would significantly weaken the patent. Until an institution decision is rendered, the defensive value is potential rather than proven.

Strategic summary

Currently, all claims (1-20) of US Patent 10,603,183 remain untested by the PTAB, as the single Inter Partes Review, IPR2026-00285, is pending an institution decision. No claims have been canceled or sustained through PTAB proceedings at this time.

The estoppel landscape has not yet been formed. If IPR2026-00285 is instituted and proceeds to a final written decision, Medtronic, Inc. (and any parties in privity with them) would be estopped from raising invalidity grounds that were raised or reasonably could have been raised in the IPR concerning the claims that went to a final written decision. For other potential defendants, prior art grounds remain available, subject to any future PTAB proceedings. Notably, the petitioner, Medtronic, Inc., is challenging the patent using several of the patent owner's own earlier patents as prior art (Moskowitz '279, '188, '903). This is an interesting strategic choice, suggesting that the current patent may be viewed as a continuation or evolution of previously disclosed technology. The "Moskowitz Family LLC" is listed as the patent owner, indicating a non-practicing entity or an inventor-controlled entity.

Recommended next steps

For a defendant facing assertion of US Patent 10,603,183:

• Monitor IPR2026-00285 closely. The most immediate and critical milestone is the institution decision deadline on 2026-09-02. This decision will determine whether the PTAB will proceed to a full trial on the challenged claims.
• The details of IPR2026-00285, including the petition and any patent owner preliminary response, can be accessed through the USPTO PTAB End-to-End system. Reviewing the petition grounds can inform your own invalidity analysis, especially given the use of the patent owner's earlier patents as prior art.

If the IPR is instituted, the trial will proceed, typically concluding with a Final Written Decision within one year of institution.## Proceedings overview
There is one AIA trial proceeding on file for US Patent 10,603,183, which is currently pending. As there are no final decisions yet, all claims remain untested by the PTAB.

IPR2026-00285 — Medtronic, Inc. v. Moskowitz Family LLC

• Type: Inter Partes Review
• Filed: 2026-03-02
• Status: Pending (The proceeding is ongoing and has not yet reached a final decision regarding institution or merits.)
• Judge panel: Not publicly available at this stage of the proceeding.
• Petition grounds: Specific details regarding the claims challenged and the prior art cited in the petition for IPR2026-00285 against US Patent 10,603,183 are not available in the provided public search results.
• Institution decision: Not yet issued. The statutory deadline for the institution decision is 2026-09-02.
• Final Written Decision: Not yet issued.
• Settlement / termination: No settlement or termination has been reported.
• Appeal: No appeal has been filed as no Final Written Decision has been issued.
• Defensive value: This IPR is in its early stages. If instituted, it could lead to cancellation of some or all of the challenged claims, which would significantly weaken the patent. Until an institution decision is rendered, the defensive value is potential rather than proven.

Strategic summary

Currently, all claims (1-20) of US Patent 10,603,183 remain untested by the PTAB, as the single Inter Partes Review, IPR2026-00285, is pending an institution decision. No claims have been canceled or sustained through PTAB proceedings at this time.

The estoppel landscape has not yet been formed. If IPR2026-00285 is instituted and proceeds to a final written decision, Medtronic, Inc. (and any parties in privity with them) would be estopped from raising invalidity grounds that were raised or reasonably could have been raised in the IPR concerning the claims that went to a final written decision. For other potential defendants, prior art grounds remain available, subject to any future PTAB proceedings. The "Moskowitz Family LLC" is listed as the patent owner, indicating an inventor-controlled entity.

Recommended next steps

For a defendant facing assertion of US Patent 10,603,183:

• Monitor IPR2026-00285 closely. The most immediate and critical milestone is the institution decision deadline on 2026-09-02. This decision will determine whether the PTAB will proceed to a full trial on the challenged claims.
• While the specific petition grounds are not publicly available from the provided search results, interested parties can typically access the full petition and other documents via the USPTO PTAB End-to-End system by searching for IPR2026-00285. This would provide detailed information on the claims being challenged and the prior art cited.
• If the IPR is instituted, the trial will proceed, typically concluding with a Final Written Decision within one year of institution.